CYREX™ ANNOUNCES THE ADDITION OF THREE NEW ARRAYS TO ITS FAMILY OF PANELS

Assess and Monitor At-Risk Autoimmune Patients

PHOENIX, AZ, August 1, 2012 - Cyrex Laboratories has announced the expansion of its family of autoimmune reactivity panels and screens with the addition of three new arrays specifically for the assessment and monitoring of Diabetes, Neurological and Joint autoimmune conditions.

“These new arrays will allow doctors to assess the treatment effectiveness, monitor disease pathogenesis and predict flares in certain autoimmune disorders,” stated Jean Bellin, president, Cyrex Laboratories. “We are extremely pleased to empower our doctors with these new clinical practice tools.”

These highly-specific screens may also be used as a follow-up to the Array 5 Multiple Autoimmune Reactivity Screen™ or be used as an initial screening for autoimmune reactivity against specific tissue groups.

The Array 6 - Diabetes Autoimmune Reactivity Screen™, Array 7 - Neurological Autoimmune Reactivity Screen™, and Array 8 - Joint Autoimmune Reactivity Screen™ will be available September 1, 2012.

About Cyrex Laboratories

Cyrex™ is a Clinical Immunology Laboratory Specializing in Autoimmunity. Cyrex offers multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Cyrex develops innovative arrays through continuous collaboration with leading experts in medical research and clinical practice. For more information, visit www.cyrexlabs.com.

Cyrex and the Cyrex logo are registered trademarks of Cyrex Laboratories. Other trademarks and registered trademarks are the property of the companies with which they are associated.